Study protocol of REGOSARC trial: Activity and safety of regorafenib in advanced soft tissue sarcoma: A multinational, randomized, placebo-controlled, phase II trial

BMC Cancer

Volumn 15, Issue 1, 2015, Pages

  Brodowicz, Thomas ^a   Liegl Atzwager, Bernadette ^b   Tresch, Emmanuelle ^c   Taieb, Sophie ^c   Kramar, Andrew ^c,d   Gruenwald, Viktor ^e   Vanseymortier, Marie ^c   Clisant, Stéphanie ^c,d   Blay, Jean Yves ^f   Cesne, Axel ^g   Penel, Nicolas ^c,d  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b MEDICAL UNIVERSITY OF GRAZ   (Austria)

^c CENTRE OSCAR LAMBRET   (France)

^d SIRIC OncoLille   (France)

^e HANNOVER MEDICAL SCHOOL   (Germany)

^f CENTRE LÉON BÉRARD   (France)

^g INSTITUT GUSTAVE ROUSSY   (France)

Author keywords

Angiogenesis; Placebo controlled trial; Progression free survival; Randomized phase II trial; Regorafenib; Sarcoma

Indexed keywords

DOXORUBICIN; PAZOPANIB; PLACEBO; REGORAFENIB; CARBANILAMIDE DERIVATIVE; PYRIDINE DERIVATIVE;

ADULT; ADVANCED CANCER; ALOPECIA; ANOREXIA; ARTICLE; AUSTRIA; CANCER GROWTH; CANCER SURGERY; CANCER SURVIVAL; CONSTIPATION; CONTROLLED STUDY; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; FATIGUE; FEMALE; FRANCE; GERMANY; HAND FOOT SYNDROME; HISTOPATHOLOGY; HOARSENESS; HUMAN; HUMAN TISSUE; HYPERTENSION; LEIOMYOSARCOMA; LIPOSARCOMA; MACULOPAPULAR RASH; MALE; METASTASIS; MYALGIA; NAUSEA; OPEN STUDY; ORAL MUCOSITIS; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL; SKIN MANIFESTATION; SOFT TISSUE SARCOMA; SURVIVAL RATE; SYNOVIAL SARCOMA; TRANSLATIONAL RESEARCH; TREATMENT DURATION; VOICE DISORDER; CLINICAL TRIAL; DISEASE FREE SURVIVAL; FOLLOW UP; MULTICENTER STUDY; SARCOMA; TREATMENT OUTCOME;

AUSTRIA; DISEASE-FREE SURVIVAL; DOUBLE-BLIND METHOD; FEMALE; FOLLOW-UP STUDIES; FRANCE; GERMANY; HUMANS; MALE; PHENYLUREA COMPOUNDS; PYRIDINES; SARCOMA; TREATMENT OUTCOME;

EID: 84925334539     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/s12885-015-1143-y     Document Type: Article

References (20)

1. Sleijfer S, Seynaeve C, Verweij J. Using single-agent therapy in adult patients with advanced soft tissue sarcoma can still be considered standard care. Oncologist. 2005;10:833-41.
2. Penel N, Van Glabbeke M, Marreaud S, Ouali M, Hohenberger P, Blay JY. Testing new regimes in patients with advanced soft tissue sarcoma: analysis of publications from the last 10years. Ann Oncol. 2011;22:1266-72.
3. Demetri GD, Chawla SP, von Mehren M, Ritch P, Baker LH, Blay JY, et al. Efficacy and safety of trabectedin in patients with advanced or metastatic liposarcoma or leiomyosarcoma after failure of prior anthracyclines and ifosfamide: results of a randomized phase II study of two different schedules. J Clin Oncol. 2009;27:4188-96.
4. Maki RG, Wathen JK, Patel SR, Priebat DA, Okuno SH, Samuels B, et al. Randomized phase II study of gemcitabine and docetaxel compared with gemcitabine alone in patients with metastatic soft tissue sarcomas: Results of sarcoma alliance for research through collaboration study 002. J Clin Oncol. 2007;25:2755-63.
5. Sleijfer S, Ray-Coquard I, Papai Z, Le Cesne A, Scurr M, Schoffski P, et al. Pazopanib, a multikinase angiogenesis inhibitor, in patients with relapsed or refractory advanced soft tissue sarcoma: a phase II study from the European organisation for research and treatment of cancer-soft tissue and bone sarcoma group (EORTC study 62043). J Clin Oncol. 2009;27:3126-32.
6. Potti A, Ganti AK, Tendulkar K, Sholes K, Chitajallu S, Koch M, et al. Determination of vascular endothelial growth factor (VEGF) overexpression in soft tissue sarcomas and the role in leiomyosarcoma. J Cancer Res Clin Oncol. 2004;130:52-6.
7. Pakos EE, Goussia AC, Tsekeris PG, Papachristou DJ, Stefanou D, Agnantis NJ. Expression of vascular endothelial growth factor and its receptor, KDR/Flk-1, in soft tissue sarcomas. Anticancer Res. 2005;25:3591-6.
8. Chao C, Al-Saleem T, Brooks JJ, Rogatko A, Kraybill WG, Eisenberg B. Vascular endothelial growth factor and soft tissue sarcomas: Tumor expression correlated with grade. Ann Surg Oncol. 2001;8:260-7.
9. Yudoh K, Kanamori M, Ohmori K, Yasuda T, Aoki M, Kimura T. Concentration of vascular endothelial growth factor in the tumour tissue as a prognostic factor of soft tissue sarcomas. Br J Cancer. 2001;84:1610-5.
10. Graeven U, Andre N, Achilles E, Zornig C, Schmiegel W. Serum levels of vascular endothelial growth factor and basic fibroblast growth factor in patients with softtissue sarcoma. J Cancer Res Clin Oncol. 1999;125:577-81.
11. Hayes AJ, Mostyn-Jones A, Koban MU, A'Hern R, Burton P, Thomas JM. Serum vascular endothelial growth factor as a tumour marker in soft tissue sarcoma. Br J Surg. 2004;91:242-7.
12. Yoon SS, Segal NH, Olshen AB, Brennan MF, Singer S. Circulating angiogenic factor levels correlate with extent of disease and risk of recurrence in patients with soft-tissue sarcoma. Ann Oncol. 2004;15:1261-6.
13. Yoon SS, Segal NH, Park PJ, Detwiller KY, Fernando NT, Ryeom SW, et al. Angiogenic profile of soft tissue sarcomas based on analysis of circulating factors and microarray gene expression. J Surg Res. 2006;135:282-90.
14. WT V d g, Blay JY, Chawal SP, Kim DW, Bui-Nguyen B, Casali PG, et al. Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomized, double-blind, placebo-controlled phase 3 trial. Lancet. 2012;379:1879-86.
15. Mross K, Frost A, Steinbild S, Hedbom S, Büchert M, Fasol U, et al. A phase I dose-escalation study of oral Regorafenib (BAY 73-4506), An Inhibitor of oncogenic, angiogenic and stromal kinases, in patients with advanced solid tumors. Clin Cancer Res. 2012;18:2658-67.
16. Wilhem SM, Dumas J, Adnane L, Lynch M, Carter CA, Schütz G, et al. Regorafenib (BAY 73-4506): a new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kiases with potent preclinical antitumor activity. Int J Cancer. 2011;129:245-55.
17. Grothey A, Van Cutsem E, Sobrero A, Siena S, Falcone A, Ychou M, et al. Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet. 2013;381:303-12.
18. Demetri GD, Reichardt P, Kang YK, Blay JY, Rutkowski P, Gelderblom H, et al. Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet. 2013;381:295-302.
19. Cousin S, Blay JY, Bertucci F, Isambert N, Italiano A, Bompas E, et al. Correlation between overall survival and growth modulation index in pre-treated sarcoma patients: a study from the French Sarcoma Group. Ann Oncol. 2013;24:2681-5.
20. Rubinstein LV, Korn EL, Freidlin B, Hunsberger S, Ivy SP, Smith MA. Design issues of randomized phase II trials and a proposal for phase II screening trials. J Clin Oncol. 2005;23:7199-206.